ArticleJournal of clinical medicine2018
The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer.
Article in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Extracellular vesicle biomarkers for pancreatic cancer diagnosis: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic cancer families.United European gastroenterology journal · 2024Article
- Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review.International journal of molecular sciences · 2024Review
- Review
- Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.International journal of molecular sciences · 2023Review
- Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning.PloS one · 2023Article
- Article
- Review
- Extracellular vesicles in pancreatic cancer progression and therapies.Cell death & disease · 2021Review
- Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?Cancers · 2021Review
- Graphene-Assisted Electrochemical Sensor for Detection of Pancreatic Cancer Markers.Frontiers in chemistry · 2021Review
- Extracellular Vesicle-Based Detection of Pancreatic Cancer.Frontiers in cell and developmental biology · 2021Article
- MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer.Molecular biology reports · 2020Review
- Review
- Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy.Cancer biology & therapy · 2020Article
- Lipocalin-2 expression and function in pancreatic diseases.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2020Review
- An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma.Cancers · 2020Article
- Non-coding RNAs in Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2020Review
- miR-499a promotes PANC-1 cell proliferation by down-regulating PDCD4 expression in pancreatic ductal adenocarcinoma.International journal of clinical and experimental pathology · 2020Article
- Familial Pancreatic Cancer: Current Perspectives.Cancer management and research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
Individuals at risk (IAR) of familial pancreatic cancer (FPC) are good candidates for screening. Unfortunately, neither reliable imaging modalities nor biomarkers are available to detect high-grade precursor lesions or early cancer. Circulating levels of candidate biomarkers LCN2, TIMP1, Glypican-1, RNU2-1f, and miRNA-196b were analyzed in 218 individuals with sporadic pancreatic ductal adenocarcinoma (PDAC,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.